Literature DB >> 18353697

Molecular consequences of the pathogenic mutation in feline GM1 gangliosidosis.

Douglas R Martin1, Brigitte A Rigat, Polly Foureman, G S Varadarajan, Misako Hwang, Barbara K Krum, Bruce F Smith, John W Callahan, Don J Mahuran, Henry J Baker.   

Abstract

G(M1) gangliosidosis is an inherited, fatal neurodegenerative disease caused by deficiency of lysosomal beta-d-galactosidase (EC 3.2.1.23) and consequent storage of undegraded G(M1) ganglioside. To characterize the genetic mutation responsible for feline G(M1) gangliosidosis, the normal sequence of feline beta-galactosidase cDNA first was defined. The feline beta-galactosidase open reading frame is 2010 base pairs, producing a protein of 669 amino acids. The putative signal sequence consists of amino acids 1-24 of the beta-galactosidase precursor protein, which contains seven potential N-linked glycosylation sites, as in the human protein. Overall sequence homology between feline and human beta-galactosidase is 74% for the open reading frame and 82% for the amino acid sequence. After normal beta-galactosidase was sequenced, the mutation responsible for feline G(M1) gangliosidosis was defined as a G to C substitution at position 1448 of the open reading frame, resulting in an amino acid substitution at arginine 483, known to cause G(M1) gangliosidosis in humans. Feline beta-galactosidase messenger RNA levels were normal in cerebral cortex, as determined by quantitative RT-PCR assays. Although enzymatic activity is severely reduced by the mutation, a full-length feline beta-galactosidase cDNA restored activity in transfected G(M1) fibroblasts to 18-times normal. beta-Galactosidase protein levels in G(M1) tissues were normal on Western blots, but immunofluorescence analysis demonstrated that the majority of mutant beta-galactosidase protein did not reach the lysosome. Additionally, G(M1) cat fibroblasts demonstrated increased expression of glucose-related protein 78/BiP and protein disulfide isomerase, suggesting that the unfolded protein response plays a role in pathogenesis of feline G(M1) gangliosidosis.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18353697      PMCID: PMC2910747          DOI: 10.1016/j.ymgme.2008.02.004

Source DB:  PubMed          Journal:  Mol Genet Metab        ISSN: 1096-7192            Impact factor:   4.797


  58 in total

1.  Characterization of beta-galactosidase mutations Asp332-->Asn and Arg148-->Ser, and a polymorphism, Ser532-->Gly, in a case of GM1 gangliosidosis.

Authors:  S Zhang; R Bagshaw; W Hilson; Y Oho; A Hinek; J T Clarke; J W Callahan
Journal:  Biochem J       Date:  2000-06-15       Impact factor: 3.857

2.  Cleavage of structural proteins during the assembly of the head of bacteriophage T4.

Authors:  U K Laemmli
Journal:  Nature       Date:  1970-08-15       Impact factor: 49.962

Review 3.  Molecular basis of GM1 gangliosidosis and Morquio disease, type B. Structure-function studies of lysosomal beta-galactosidase and the non-lysosomal beta-galactosidase-like protein.

Authors:  J W Callahan
Journal:  Biochim Biophys Acta       Date:  1999-10-08

4.  Generalized CNS disease and massive GM1-ganglioside accumulation in mice defective in lysosomal acid beta-galactosidase.

Authors:  C N Hahn; M del Pilar Martin; M Schröder; M T Vanier; Y Hara; K Suzuki; K Suzuki; A d'Azzo
Journal:  Hum Mol Genet       Date:  1997-02       Impact factor: 6.150

5.  GM1 gangliosidosis in shiba dogs.

Authors:  O Yamato; K Ochiai; Y Masuoka; E Hayashida; M Tajima; S Omae; M Iijima; T Umemura; Y Maede
Journal:  Vet Rec       Date:  2000-04-22       Impact factor: 2.695

6.  Parenteral and mucosal prime-boost immunization strategies in mice with hepatitis B surface antigen and CpG DNA.

Authors:  Michael J McCluskie; Risini D Weeratna; Paul J Payette; Heather L Davis
Journal:  FEMS Immunol Med Microbiol       Date:  2002-02-18

7.  An inversion of 25 base pairs causes feline GM2 gangliosidosis variant.

Authors:  Douglas R Martin; Barbara K Krum; G S Varadarajan; Terri L Hathcock; Bruce F Smith; Henry J Baker
Journal:  Exp Neurol       Date:  2004-05       Impact factor: 5.330

8.  GM1-ganglioside-mediated activation of the unfolded protein response causes neuronal death in a neurodegenerative gangliosidosis.

Authors:  Alessandra Tessitore; Maria del P Martin; Renata Sano; Yanjun Ma; Linda Mann; Angela Ingrassia; Eric D Laywell; Dennis A Steindler; Linda M Hendershot; Alessandra d'Azzo
Journal:  Mol Cell       Date:  2004-09-10       Impact factor: 17.970

9.  A novel mutation in the gene for canine acid beta-galactosidase that causes GM1-gangliosidosis in Shiba dogs.

Authors:  O Yamato; D Endoh; A Kobayashi; Y Masuoka; M Yonemura; A Hatakeyama; H Satoh; M Tajima; M Yamasaki; Y Maede
Journal:  J Inherit Metab Dis       Date:  2002-10       Impact factor: 4.982

10.  Neuronal GM1 gangliosidosis in a Siamese cat with beta-galactosidase deficiency.

Authors:  H J Baker; J R Lindsey; G M McKhann; D F Farrell
Journal:  Science       Date:  1971-11-19       Impact factor: 47.728

View more
  19 in total

1.  Removal of potentially confounding phenotypes from a Siamese-derived feline glaucoma breeding colony.

Authors:  Michelle M Rutz-Mendicino; Elizabeth M Snella; Jackie K Jens; Barbara Gandolfi; Steven A Carlson; Markus H Kuehn; Gillian J McLellan; N Matthew Ellinwood
Journal:  Comp Med       Date:  2011-06       Impact factor: 0.982

2.  A sensitive fluorescence-based assay for monitoring GM2 ganglioside hydrolysis in live patient cells and their lysates.

Authors:  Michael B Tropak; Scott W Bukovac; Brigitte A Rigat; Sayuri Yonekawa; Warren Wakarchuk; Don J Mahuran
Journal:  Glycobiology       Date:  2009-11-16       Impact factor: 4.313

Review 3.  The GM1 and GM2 Gangliosidoses: Natural History and Progress toward Therapy.

Authors:  Debra S Regier; Richard L Proia; Alessandra D'Azzo; Cynthia J Tifft
Journal:  Pediatr Endocrinol Rev       Date:  2016-06

4.  Intermittent enzyme replacement therapy with recombinant human β-galactosidase prevents neuraminidase 1 deficiency

Authors:  Amanda R Luu; Cara Wong; Vishal Agrawal; Nathan Wise; Britta Handyside; Melanie J Lo; Glenn Pacheco; Jessica B Felix; Alexander Giaramita; Alessandra d'Azzo; Jon Vincelette; Sherry Bullens; Stuart Bunting; Terri M Christianson; Charles M Hague; Jonathan H LeBowitz; Gouri Yogalingam
Journal:  J Biol Chem       Date:  2020-07-28       Impact factor: 5.157

5.  Sustained normalization of neurological disease after intracranial gene therapy in a feline model.

Authors:  Victoria J McCurdy; Aime K Johnson; Heather L Gray-Edwards; Ashley N Randle; Brandon L Brunson; Nancy E Morrison; Nouha Salibi; Jacob A Johnson; Misako Hwang; Ronald J Beyers; Stanley G Leroy; Stacy Maitland; Thomas S Denney; Nancy R Cox; Henry J Baker; Miguel Sena-Esteves; Douglas R Martin
Journal:  Sci Transl Med       Date:  2014-04-09       Impact factor: 17.956

6.  Bis(monoacylglycero)phosphate: a secondary storage lipid in the gangliosidoses.

Authors:  Zeynep Akgoc; Miguel Sena-Esteves; Douglas R Martin; Xianlin Han; Alessandra d'Azzo; Thomas N Seyfried
Journal:  J Lipid Res       Date:  2015-03-20       Impact factor: 5.922

7.  Evaluation of N-nonyl-deoxygalactonojirimycin as a pharmacological chaperone for human GM1 gangliosidosis leads to identification of a feline model suitable for testing enzyme enhancement therapy.

Authors:  Brigitte A Rigat; Michael B Tropak; Justin Buttner; Ellen Crushell; Daphne Benedict; John W Callahan; Douglas R Martin; Don J Mahuran
Journal:  Mol Genet Metab       Date:  2012-06-19       Impact factor: 4.797

8.  Identification and characterization of ambroxol as an enzyme enhancement agent for Gaucher disease.

Authors:  Gustavo H B Maegawa; Michael B Tropak; Justin D Buttner; Brigitte A Rigat; Maria Fuller; Deepangi Pandit; Liangiie Tang; Gregory J Kornhaber; Yoshitomo Hamuro; Joe T R Clarke; Don J Mahuran
Journal:  J Biol Chem       Date:  2009-07-03       Impact factor: 5.157

9.  Therapeutic response in feline sandhoff disease despite immunity to intracranial gene therapy.

Authors:  Allison M Bradbury; J Nicholas Cochran; Victoria J McCurdy; Aime K Johnson; Brandon L Brunson; Heather Gray-Edwards; Stanley G Leroy; Misako Hwang; Ashley N Randle; Laura S Jackson; Nancy E Morrison; Rena C Baek; Thomas N Seyfried; Seng H Cheng; Nancy R Cox; Henry J Baker; M Begona Cachón-González; Timothy M Cox; Miguel Sena-Esteves; Douglas R Martin
Journal:  Mol Ther       Date:  2013-05-21       Impact factor: 11.454

10.  Diltiazem, a L-type Ca(2+) channel blocker, also acts as a pharmacological chaperone in Gaucher patient cells.

Authors:  Brigitte Rigat; Don Mahuran
Journal:  Mol Genet Metab       Date:  2009-01-22       Impact factor: 4.797

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.